148 related articles for article (PubMed ID: 35324456)
1. Oophorectomy improves pituitary activin inhibitory function preventing lactotroph hyperplasia development.
Peña-Zanoni M; Faraoni EY; Abeledo-Machado A; Perez PA; Marcial López CA; Camilletti MA; Gutierrez S; Rulli SB; Diaz-Torga G
Endocr Relat Cancer; 2022 May; 29(6):359-373. PubMed ID: 35324456
[TBL] [Abstract][Full Text] [Related]
2. Activin-inhibitory action on lactotrophs is decreased in lactotroph hyperplasia.
Faraoni EY; Abeledo Machado AI; Pérez PA; Marcial López CA; Camilletti MA; Peña-Zanoni M; Rulli SB; Gutiérrez S; Díaz-Torga G
J Endocrinol; 2020 Feb; 244(2):415-429. PubMed ID: 32395971
[TBL] [Abstract][Full Text] [Related]
3. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
4. Sex-specific regulation of prolactin secretion by pituitary activins in postnatal development.
Abeledo-Machado A; Bornancini D; Peña-Zanoni M; Camilletti MA; Faraoni EY; Díaz-Torga G
J Endocrinol; 2023 Sep; 258(3):. PubMed ID: 37399522
[TBL] [Abstract][Full Text] [Related]
5. The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.
Recouvreux MV; Camilletti MA; Rifkin DB; Díaz-Torga G
J Endocrinol; 2016 Mar; 228(3):R73-83. PubMed ID: 26698564
[TBL] [Abstract][Full Text] [Related]
6. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice.
Asa SL; Kelly MA; Grandy DK; Low MJ
Endocrinology; 1999 Nov; 140(11):5348-55. PubMed ID: 10537166
[TBL] [Abstract][Full Text] [Related]
7. ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation.
Principe M; Chanal M; Karam V; Wierinckx A; Mikaélian I; Gadet R; Auger C; Raverot V; Jouanneau E; Vasiljevic A; Hennino A; Raverot G; Bertolino P
Endocr Relat Cancer; 2018 Sep; 25(9):795-806. PubMed ID: 30012586
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in the development of prolactinoma in mice overexpressing hCGβ: role of TGFβ1.
Faraoni EY; Camilletti MA; Abeledo-Machado A; Ratner LD; De Fino F; Huhtaniemi I; Rulli SB; Díaz-Torga G
J Endocrinol; 2017 Mar; 232(3):535-546. PubMed ID: 28096433
[TBL] [Abstract][Full Text] [Related]
9. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-7a2 Regulates Prolactin in Developing Lactotrophs and Prolactinoma Cells.
LaPierre MP; Godbersen S; Torres Esteban M; Schad AN; Treier M; Ghoshdastider U; Stoffel M
Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33248443
[TBL] [Abstract][Full Text] [Related]
11. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.
Schuff KG; Hentges ST; Kelly MA; Binart N; Kelly PA; Iuvone PM; Asa SL; Low MJ
J Clin Invest; 2002 Oct; 110(7):973-81. PubMed ID: 12370275
[TBL] [Abstract][Full Text] [Related]
12. Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen.
Mukdsi JH; De Paul AL; Muñoz S; Aoki A; Torres AI
Histochem Cell Biol; 2004 Jun; 121(6):453-62. PubMed ID: 15221415
[TBL] [Abstract][Full Text] [Related]
13. Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas.
McAndrew J; Paterson AJ; Asa SL; McCarthy KJ; Kudlow JE
Endocrinology; 1995 Oct; 136(10):4479-88. PubMed ID: 7664668
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
15. mPRs represent a novel target for PRL inhibition in experimental prolactinomas.
Camilletti MA; Abeledo-Machado A; Perez PA; Faraoni EY; De Fino F; Rulli SB; Ferraris J; Pisera D; Gutierrez S; Thomas P; Díaz-Torga G
Endocr Relat Cancer; 2019 May; 26(5):497-510. PubMed ID: 30856609
[TBL] [Abstract][Full Text] [Related]
16. Ept7, a quantitative trait locus that controls estrogen-induced pituitary lactotroph hyperplasia in rat, is orthologous to a locus in humans that has been associated with numerous cancer types and common diseases.
Dennison KL; Chack AC; Hickman MP; Harenda QE; Shull JD
PLoS One; 2018; 13(9):e0204727. PubMed ID: 30261014
[TBL] [Abstract][Full Text] [Related]
17. New insights into progesterone actions on prolactin secretion and prolactinoma development.
Camilletti MA; Abeledo-Machado A; Faraoni EY; Thomas P; Díaz-Torga G
Steroids; 2019 Dec; 152():108496. PubMed ID: 31521709
[TBL] [Abstract][Full Text] [Related]
18. Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development.
Kuchenbauer F; Theodoropoulou M; Hopfner U; Stalla J; Renner U; Tonn JC; Low MJ; Arzt E; Stalla GK; Páez-Pereda M
Mol Cell Endocrinol; 2003 Sep; 207(1-2):13-20. PubMed ID: 12972179
[TBL] [Abstract][Full Text] [Related]
19. Sex-specific Regulation of Prolactin Secretion by Pituitary Bradykinin Receptors.
Abeledo-Machado A; Peña-Zanoni M; Bornancini D; Camilletti MA; Faraoni EY; Marcial A; Rulli S; Alhenc-Gelas F; Díaz-Torga GS
Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35863039
[TBL] [Abstract][Full Text] [Related]
20. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
